By Dr David Reynolds - Chief Executive Officer of LoQus23 Therapeutics2025-02-28T11:39:52
This Friday, February 28, marks Rare Disease Day 2025, a global initiative raising awareness for the 300 million people living with rare conditions. Dr David Reynolds, CEO of LoQus23 Therapeutics, explores how advancements in rare disease research are driving the development of new treatments.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2023-07-04T09:00:08
Sponsored by SB Drug Discovery
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2023-03-20T13:41:33
Sponsored by Bio-Techne
2023-06-13T13:30:40
Sponsored by NanoTemper Technologies
2023-11-20T13:43:43
Sponsored by Merck
Site powered by Webvision Cloud